Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sab Biotherapeutics Inc (NQ: SABS ) 2.920 -0.170 (-5.50%) Streaming Delayed Price Updated: 3:42 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 3,848 Open 3.070 Bid (Size) 2.880 (1) Ask (Size) 3.070 (6) Prev. Close 3.090 Today's Range 2.920 - 3.070 52wk Range 2.360 - 10.50 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 20, 2024 Via Benzinga SAb Biotherapeutics Rebrands as SAB BIO June 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Performance YTD -58.29% -58.29% 1 Month -10.15% -10.15% 3 Month -36.52% -36.52% 6 Month -52.52% -52.52% 1 Year -67.17% -67.17% More News Read More 12 Health Care Stocks Moving In Wednesday's After-Market Session June 19, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session June 18, 2024 Via Benzinga SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions June 18, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Departure of Chief Financial Officer May 30, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session May 23, 2024 Via Benzinga SABS Stock Earnings: SAB Biotherapeutics Misses EPS for Q1 2024 May 21, 2024 Via InvestorPlace FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics May 21, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates May 20, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors May 06, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Provides SAB-142 Trial Update April 16, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at INNODIA Annual Meeting April 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference April 04, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment March 25, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the BIO CEO & Investor Conference February 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference February 08, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Announces Executive Leadership Change February 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement January 23, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 05, 2024 Via Benzinga Cal-Maine Foods, UniFirst And 3 Stocks To Watch Heading Into Wednesday January 03, 2024 Via Benzinga SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split January 02, 2024 From SAB Biotherapeutics, Inc. Via GlobeNewswire VerifyMe And 3 Other Stocks Under $2 Insiders Are Buying December 01, 2023 Via Benzinga Topics Stocks Exposures US Equities SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes November 29, 2023 From SAB Biotherapeutics, Inc. Via GlobeNewswire EXCLUSIVE: SAB Biotherapeutics Kickstarts Phase 1 Study For Its Lead Type 1 Diabetes Hopeful In Australia November 29, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.